Cargando…

Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC)

Stereotactic body radiotherapy (SBRT) applies high doses and requires advanced techniques to spare surrounding tissue in the presence of organ motion. In this work patient individual phase gating is investigated. We studied peripheral and central primary lung tumors. The internal target volume (ITV)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraus, K. M., Oechsner, M., Wilkens, J. J., Kessel, K. A., Münch, S., Combs, S. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955128/
https://www.ncbi.nlm.nih.gov/pubmed/33712667
http://dx.doi.org/10.1038/s41598-021-85031-w
_version_ 1783664198528532480
author Kraus, K. M.
Oechsner, M.
Wilkens, J. J.
Kessel, K. A.
Münch, S.
Combs, S. E.
author_facet Kraus, K. M.
Oechsner, M.
Wilkens, J. J.
Kessel, K. A.
Münch, S.
Combs, S. E.
author_sort Kraus, K. M.
collection PubMed
description Stereotactic body radiotherapy (SBRT) applies high doses and requires advanced techniques to spare surrounding tissue in the presence of organ motion. In this work patient individual phase gating is investigated. We studied peripheral and central primary lung tumors. The internal target volume (ITV) was defined including different numbers of phases picked from a 4D Computed tomography (CT) defining the gating window (gw). Planning target volume (PTV) reductions depending on the gw were analyzed. A treatment plan was calculated on a reference phase CT (rCT) and the dose for each breathing phase was calculated and accumulated on the rCT. We compared the dosimetric results with the dose calculated when all breathing phases were included for ITV definition. GWs including 1 to 10 breathing phases were analyzed. We found PTV reductions up to 38.4%. The mean reduction of the lung volume receiving 20 Gy due to gating was found to be 25.7% for peripheral tumors and 16.7% for central tumors. Gating considerably reduced esophageal doses. However, we found that simple reduction of the gw does not necessarily influence the dose in a clinically relevant range. Thus, we suggest a patient individual definition of the breathing phases included within the gw.
format Online
Article
Text
id pubmed-7955128
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79551282021-03-15 Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC) Kraus, K. M. Oechsner, M. Wilkens, J. J. Kessel, K. A. Münch, S. Combs, S. E. Sci Rep Article Stereotactic body radiotherapy (SBRT) applies high doses and requires advanced techniques to spare surrounding tissue in the presence of organ motion. In this work patient individual phase gating is investigated. We studied peripheral and central primary lung tumors. The internal target volume (ITV) was defined including different numbers of phases picked from a 4D Computed tomography (CT) defining the gating window (gw). Planning target volume (PTV) reductions depending on the gw were analyzed. A treatment plan was calculated on a reference phase CT (rCT) and the dose for each breathing phase was calculated and accumulated on the rCT. We compared the dosimetric results with the dose calculated when all breathing phases were included for ITV definition. GWs including 1 to 10 breathing phases were analyzed. We found PTV reductions up to 38.4%. The mean reduction of the lung volume receiving 20 Gy due to gating was found to be 25.7% for peripheral tumors and 16.7% for central tumors. Gating considerably reduced esophageal doses. However, we found that simple reduction of the gw does not necessarily influence the dose in a clinically relevant range. Thus, we suggest a patient individual definition of the breathing phases included within the gw. Nature Publishing Group UK 2021-03-12 /pmc/articles/PMC7955128/ /pubmed/33712667 http://dx.doi.org/10.1038/s41598-021-85031-w Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Kraus, K. M.
Oechsner, M.
Wilkens, J. J.
Kessel, K. A.
Münch, S.
Combs, S. E.
Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC)
title Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC)
title_full Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC)
title_fullStr Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC)
title_full_unstemmed Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC)
title_short Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC)
title_sort patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (nsclc)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955128/
https://www.ncbi.nlm.nih.gov/pubmed/33712667
http://dx.doi.org/10.1038/s41598-021-85031-w
work_keys_str_mv AT krauskm patientindividualphasegatingforstereotacticradiationtherapyofearlystagenonsmallcelllungcancernsclc
AT oechsnerm patientindividualphasegatingforstereotacticradiationtherapyofearlystagenonsmallcelllungcancernsclc
AT wilkensjj patientindividualphasegatingforstereotacticradiationtherapyofearlystagenonsmallcelllungcancernsclc
AT kesselka patientindividualphasegatingforstereotacticradiationtherapyofearlystagenonsmallcelllungcancernsclc
AT munchs patientindividualphasegatingforstereotacticradiationtherapyofearlystagenonsmallcelllungcancernsclc
AT combsse patientindividualphasegatingforstereotacticradiationtherapyofearlystagenonsmallcelllungcancernsclc